In a pathology lab, a cancer diagnosis begins not with an algorithm, but with a barcode. A glass slide is scanned, creating a massive digital image, and then it must be tracked, managed, and routed to the right expert. For Virasoft, an eight-year-old company operating between New York and Istanbul, this unglamorous workflow is the critical wedge. The company reports its software now handles 400,000 diagnostic cases annually across more than 20 institutions [Virasoft website].
The workflow-first wedge
While competitors like PathAI and Paige often lead with flashy AI algorithms, Virasoft's public positioning emphasizes the foundational plumbing. Its core product is APLIS, an Anatomic Pathology Laboratory Information System designed to manage lab operations via barcode tracking and sample logistics [Perplexity Sonar Pro]. This is paired with a CE-IVDR certified Image Management System [Perplexity Sonar Pro]. The company's AI-based decision support tools are presented as an integrated layer atop this certified workflow backbone.
Traction in a regulated landscape
The company's reported scale, 400,000 cases annually, suggests a product that has found adoption. Pathology labs have been using Virasoft's digital pathology solutions since 2019 [Perplexity Sonar Pro]. With an estimated 30 employees and revenue under $5 million, the operation remains capital-efficient, having raised only undisclosed seed rounds in 2017 and again in May 2025 [Perplexity Sonar Pro] [Crunchbase, May 2025].
| Metric | Figure | Source |
|---|---|---|
| Annual Case Volume | 400,000 | [Virasoft website] |
| Customer Institutions | 20+ | [Virasoft website] |
| Headcount | ~30 | [Perplexity Sonar Pro] |
| Revenue | <$5M | [Perplexity Sonar Pro] |
| Latest Funding | Seed (May 2025) | [Crunchbase, May 2025] |
The crowded field of digital pathology
Virasoft's path is not without formidable obstacles. It operates in a space defined by well-funded, research-heavy players. The competitive landscape presents a clear tiered structure:
- PathAI & Paige. The category leaders, with substantial venture backing and high-profile partnerships.
- Proscia. A strong contender focusing on the digital pathology platform itself.
- Virasoft. Positions itself with a cost-effective, certified workflow system that has proven adoption, particularly in Turkey and surrounding regions.
The patient at the end of the slide
For all the talk of workflows and certifications, the ultimate output is a diagnosis for a person waiting for answers. Virasoft's tools are designed for pathologists interpreting biopsies for cancers. The company's bet is that by making this digital transition reliable and regulatorily sound, it creates the essential substrate upon which more advanced AI can later be safely built.